Sientra Looks Good: $80 million Series B Could Help Build Platform
This article was originally published in Start Up
Executive Summary
A deep-pocketed syndicate--Orbimed Advisors, Clarus Ventures, TIAA-CREF and Goldman Sachs--supply $80 million to start Sientra, a seller of silicone breast implants and other aesthetics devices.
You may also be interested in...
Sientra’s “Stand-By” Series C Shows How To Eliminate Late-Stage Risk
Breast-implant start-up Sientra recently raised a $65 million Series C round at a time when venture capital for medtech is scarce, particularly for mid-stage companies pushing toward important milestones. Using a new kind of “stand-by” financing, it was ready to hit the ground running upon the recent FDA approval of its breast implants.
Device Financings: Recent Growth, Future Opportunities
In Vivo analyzed recent public and private device financings to determine the comparative strengths and weaknesses of the various types of device financings, and further broke down the investments by therapeutic categories to examine what areas are hot and which ones are not. We found that the device industry has rebounded from a dismal public market and is showing strength among both public and private investors, resulting in a sector well-positioned for continued growth.
Beauty: In the Eye of the Stakeholder
A $12-billion market and growing, the field of aesthetic medicine has exploded with new treatments and techniques for improving and restoring the quality, health and appearance of aging skin. Techniques such as tissue tightening, skin resurfacing, cellulite treatments, dermal augmentation, and fat removal are just some of the new advancements in aesthetic medicine that were highlighted at the 2007 American Academy of Dermatology meeting.